These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22898557)

  • 41. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
    Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
    Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
    Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.
    Marshall HS; Richmond PC; Nissen MD; Jiang Q; Anderson AS; Jansen KU; Reynolds G; Ziegler JB; Harris SL; Jones TR; Perez JL
    Pediatr Infect Dis J; 2012 Oct; 31(10):1061-8. PubMed ID: 22718089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults.
    Findlow H; Plikaytis BD; Aase A; Bash MC; Chadha H; Elie C; Laher G; Martinez J; Herstad T; Newton E; Viviani S; Papaspyridis C; Kulkarni P; Wilding M; Preziosi MP; Marchetti E; Hassan-King M; La Force FM; Carlone G; Borrow R
    Clin Vaccine Immunol; 2009 Jul; 16(7):969-77. PubMed ID: 19474264
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.
    Halperin SA; McDonald J; Samson L; Danzig L; Santos G; Izu A; Smith B; MacDonald N
    Clin Invest Med; 2002 Dec; 25(6):243-51. PubMed ID: 12516995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.
    Huo Z; Sinha R; McNeela EA; Borrow R; Giemza R; Cosgrove C; Heath PT; Mills KH; Rappuoli R; Griffin GE; Lewis DJ
    Infect Immun; 2005 Dec; 73(12):8256-65. PubMed ID: 16299322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians.
    Tapia MD; Sow SO; Haidara FC; Diallo F; Doumbia M; Enwere GC; Paranjape G; Hervé J; Bouma E; Parulekar V; Martellet L; Chaumont J; Plikaytis BD; Tang Y; Kulkarni PS; Hartmann K; Preziosi MP
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S507-13. PubMed ID: 26553682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.
    Stamboulian D; Lopardo G; Lopez P; Cortes-Barbosa C; Valencia A; Bedell L; Karsten A; Dull PM
    Int J Infect Dis; 2010 Oct; 14(10):e868-75. PubMed ID: 20655261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
    Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
    Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Evaluation of safety of meningococcal group AC bivalent polysaccharide conjugate vaccine in children aged 5-24 months old].
    Zhou H; Wang JY; Tan Y; Lü HY; Wang M; Cai QC; Zhang HZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):920-3. PubMed ID: 24378132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and preliminary immunogenicity of MenC/P64k, a meningococcal serogroup C conjugate vaccine with a new recombinant carrier.
    Pérez AE; Dickinson FO; Banderas F; Serrano T; Llanes R; Guzmán D; Díaz P; Alvarez A; Guirola M; Caballero E; Canaan-Haden L; Guillén G
    FEMS Immunol Med Microbiol; 2006 Apr; 46(3):386-92. PubMed ID: 16553812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.
    Tejedor JC; Omeñaca F; García-Sicilia J; Verdaguer J; Van Esso D; Esporrín C; Molina V; Muro M; Marés J; Enrubia M; Moraga F; García-Corbeira P; Dobbelaere K; Schuerman L;
    Pediatr Infect Dis J; 2004 Dec; 23(12):1109-15. PubMed ID: 15626947
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age.
    Baxter R; Baine Y; Ensor K; Bianco V; Friedland LR; Miller JM
    Pediatr Infect Dis J; 2011 Mar; 30(3):e41-8. PubMed ID: 21200360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa.
    Lee CH; Kuo WC; Beri S; Kapre S; Joshi JS; Bouveret N; LaForce FM; Frasch CE
    Vaccine; 2009 Jan; 27(5):726-32. PubMed ID: 19063929
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
    Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.
    Wong SH; Lennon DR; Jackson CM; Stewart JM; Reid S; Ypma E; O'Hallahan JM; Oster P; Mulholland K; Martin DR
    Pediatr Infect Dis J; 2009 May; 28(5):385-90. PubMed ID: 19384263
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.
    Hosking J; Rasanathan K; Mow FC; Jackson C; Martin D; O'Hallahan J; Oster P; Ypma E; Reid S; Aaberge I; Crengle S; Stewart J; Lennon D
    Clin Vaccine Immunol; 2007 Nov; 14(11):1393-9. PubMed ID: 17898183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.